North America Pharmacovigilance and Drug Safety Software Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Software Type (Adverse Event Reporting Software, Drug Safety Audits Software, Issue Tracking Software, and Fully Integrated Softwar

North America Pharmacovigilance and Drug Safety Software Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Software Type (Adverse Event Reporting Software, Drug Safety Audits Software, Issue Tracking Software, and Fully Integrated Software); Delivery Mode (On-premise, and Cloud-based); End User (Pharmaceutical and Biotech Companies, Contract Research Organizations (CROs), and Business Process Outsourcing (BPO) Firms)

The pharmacovigilance and drug safety software market in North America is expected to grow from US$ 73.4 million in 2019 to US$ 136.0 million by 2027; it is estimated to grow at a CAGR of 8% 2019-2027. Pharmacovigilance is a key component of effective drug regulation systems, clinical practices, and public health programs. The number of Adverse Drug Reactions (ADRs) reported resulted in an increase in the volume of data handled. In the current network of pharmacovigilance centers coordinated by the Uppsala Monitoring Centre, pharmacovigilance is a critical and integral part of clinical research, and it is growing in many countries. Today, many pharmacovigilance centers are working for drug safety monitoring. However, at the turn of the millennium pharmacovigilance faces major challenges in aspect of better safety and monitoring of drugs.

The centralized reporting and storage of adverse drug reaction reports would help in monitoring and preventing future adverse reaction from the drug consumption. European Medicines Agency (EMA) and US Food and Drug Administration (FDA) are strengthening the pharmacovigilance area by interacting on different topics related to post-marketing safety and scientific exchange. Discussions on priority such as biosimilars; medicines for cancer, orphan disease, and children; and blood-based products. Thus, increasing globalization in the pharmacovigilance sector helps in drug safety software. It improves the quality and efficacy of pharmacovigilance and drug safety software, which favors the growth of the pharmacovigilance and drug safety software market in North America.

The North America pharmacovigilance and drug safety software market is segmented on the bases of software type, delivery mode, and end user. In 2019, the adverse event reporting software accounted for the largest market share in the market. In pharmacovigilance, the high volume of adverse reaction report event data is generated. These reports may not be in a uniform format. Therefore, it becomes difficult to classify the event manually. Manual processing and classification of adverse event reports is costly and time-consuming operation. To overcome these challenges, companies are incorporating automated solutions. Therefore, the market growth is expected to bolster during the forecast period.

Since the COVID-19 outbreak, North America has been recording the growing number of COVID-19 confirmed cases. Several measures are being taken to restrain the disease and prevent the transmission of virus. Nevertheless, the excessive number of confirmed cases has cancelled doctor's appointment, decreased the demand for elective pharmacovigilance and drug safety software due to long period of lockdown. In the US, due to a growing number of contaminated patients, healthcare practitioners and leading organizations are distracting the flow of health services from research and development to primary care, which slows down the process of innovation. In addition, many health organizations, such as FDA, are evaluating the effects of the pandemic, and how clinical trials and pharmacovigilance programmes can be handled in the coming years. The rapidly changing situation indicates that sponsors need to be more cautious and diligent in assessing the consequences of the pandemic and shifts in authority expectations to minimize the impact on safety reporting and to ensure patient safety. The value of demanding updated guidelines and implementing regulatory changes quickly is greater than ever as it can mitigate disruption to clinical trials. To deal successfully with a highly complex situation, a proven and comprehensive safety reporting solution may be required.

The overall North America pharmacovigilance and drug safety software market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the North America pharmacovigilance and drug safety software market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants of this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the North America pharmacovigilance and drug safety software market. Veeva Systems, IQVIA Inc., Ennov, AB Cube, United Biosource LLC, ArisGlobal LLC, Sparta Systems, Oracle Corporation, Sarjen Systems Pvt. Ltd, EXTEDO, and Online Business Applications, Inc. are among the players operating in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America pharmacovigilance and drug safety software market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacovigilance and drug safety software market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the pharmacovigilance and drug safety software market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution 


1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Pharmacovigilance and Drug Safety Software Market – By Software Type
1.3.2 Pharmacovigilance and Drug Safety Software Market – By Delivery Mode
1.3.3 Pharmacovigilance and Drug Safety Software Market – By End User
1.3.4 North America Pharmacovigilance and Drug Safety Software Market – By Country
2. North America Pharmacovigilance and Drug Safety Software Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacovigilance and Drug Safety Software Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Pharmacovigilance and Drug Safety Software Market- North America PEST Analysis
4.3 Expert Opinion
5. North America Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidences of Adverse Drug Reactions (ADRs)
5.1.2 Globalization of Pharmacovigilance
5.2 Market Restraints
5.2.1 Expensive Technology
5.3 Future Trends
5.3.1 Artificial Intelligence in Pharmacovigilance
5.4 Impact Analysis
6. Pharmacovigilance and Drug Safety Software Market – North America Analysis
6.1 North America Pharmacovigilance and Drug Safety Software Market Revenue Forecasts and Analysis
7. North America Pharmacovigilance and Drug Safety Software Market Analysis and Forecasts To 2027 – By Software Type
7.1 Overview
7.2 Pharmacovigilance (PV) and Drug Safety Software Market, by Software Type, 2019 & 2027 (%)
7.3 Adverse Event Reporting Software Market
7.3.1 Overview
7.3.2 Adverse Event Reporting Software Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Drug Safety Audits Software
7.4.1 Overview
7.4.2 Drug Safety Audits Software Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Issue Tracking Software
7.5.1 Overview
7.5.2 Issue Tracking Software Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Fully Integrated Software
7.6.1 Overview
7.6.2 Fully Integrated Software Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Pharmacovigilance and Drug Safety Software Market Analysis and Forecasts To 2027 – By Delivery Mode
8.1 Overview
8.2 Pharmacovigilance (PV) and Drug Safety Software Market, By Delivery Mode 2019 & 2027 (%)
8.3 On-premise
8.3.1 Overview
8.3.2 On-premise Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Cloud- Based
8.4.1 Overview
8.4.2 Cloud Based Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Pharmacovigilance and Drug Safety Software Market Analysis and Forecasts to 2027– By End User
9.1 Overview
9.2 Pharmacovigilance (PV) and Drug Safety Software Market, By End User, 2019 & 2027 (%)
9.3 Pharmaceutical and Biotech Companies Market
9.3.1 Overview
9.3.2 Pharmaceutical and Biotech Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Contract Research Organizations (CROs) Market
9.4.1 Overview
9.4.2 Contract Research Organizations (CROs) Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Business Process Outsourcing (BPO) Firms Market
9.5.1 Overview
9.5.2 Business Process Outsourcing (BPO) Firms Market Revenue and Forecasts to 2027 (US$ Mn)
10. Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 – Geographical Analysis
10.1 North America: Pharmacovigilance and Drug Safety Software Market
10.1.1 Overview
10.1.2 North America Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Country (%)
10.1.3 US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.1 US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.2 US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type (US$ Mn)
10.1.3.3 US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
10.1.3.4 US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
10.1.4 Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.1 Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.2 Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type (US$ Mn)
10.1.4.3 Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
10.1.4.4 Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
10.1.5 Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.1 Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.2 Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type (US$ Mn)
10.1.5.3 Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
10.1.5.4 Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
11. Impact Of COVID-19 Pandemic on North America Pharmacovigilance and Drug Safety Software Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Pharmacovigilance and Drug Safety Software Market
12.3 Organic Developments
12.3.1 Overview
12.3.2 Organic Developments Done by Companies
12.4 Inorganic Developments
12.4.1 Overview
12.4.2 Inorganic Growth Strategies by Companies
13. COMPANY PROFILES
13.1 Veeva Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 IQVIA Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Ennov
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 AB Cube
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 United Biosource LLC
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 ArisGlobal LLC
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Sparta Systems
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Oracle Corporation
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Sarjen Systems Pvt. Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 EXTEDO
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Online Business Applications, Inc.
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
List of Tables
Table 1. US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type(US$ Mn)
Table 2. US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
Table 3. US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
Table 4. Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type(US$ Mn)
Table 5. Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
Table 6. Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
Table 7. Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Software Type(US$ Mn)
Table 8. Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Delivery Mode (US$ Mn)
Table 9. Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By End User (US$ Mn)
Table 10. Organic Developments Done by Companies
Table 11. Recent Inorganic Growth Strategies by the Companies
Table 12. Glossary of Terms, Pharmacovigilance and Drug Safety Software Market
List of Figures
Figure 1. Pharmacovigilance and Drug Safety Software Market Segmentation
Figure 2. North America Pharmacovigilance and Drug Safety Software Market Overview
Figure 3. Adverse Event Reporting Software Segment Held Largest Share of Software Type in Pharmacovigilance and Drug Safety Software Market
Figure 4. Contract Research Organizations Segment Held Largest Share of End User in Pharmacovigilance and Drug Safety Software Market
Figure 5. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Pharmacovigilance and Drug Safety Software Market - North America PEST Analysis
Figure 7. Pharmacovigilance and Drug Safety Software Market Impact Analysis of Driver and Restraints
Figure 8. North America Pharmacovigilance and Drug Safety Software Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Pharmacovigilance (PV) and Drug Safety Software Market, by Software Type, 2019 & 2027 (%)
Figure 10. Adverse Event Reporting Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Drug Safety Audits Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Issue Tracking Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Fully Integrated Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Pharmacovigilance (PV) and Drug Safety Software Market, by Delivery Mode 2019 & 2027 (%)
Figure 15. On-premise Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Cloud Based Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Pharmacovigilance (PV) and Drug Safety Software Market, by End User, 2019 & 2027 (%)
Figure 18. Pharmaceutical and Biotech Companies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Contract Research Organizations (CROs) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Business Process Outsourcing (BPO) Firms Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. North America Pharmacovigilance and Drug Safety Software Market Revenue Overview, By Country, 2019 (US$ Mn)
Figure 22. North America Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027, By Country (%)
Figure 23. US Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Canada Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts To 2027 (US$ Mn)
Figure 25. Mexico Pharmacovigilance and Drug Safety Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Impact of COVID-19 Pandemic in North American Country Markets
Figure 27. Growth Strategies in the Pharmacovigilance and Drug Safety Software Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings